The use of societal criteria in priority setting for health technology assessment in the Netherlands - Initial experiences and future challenges by Oortwijn, W.J. et al.
International Journal of Technology Assessment in Hearth Care, 14:2 (1998), 226-236.
Copyright © 1998 Cambridge University Press. Printed in the U.S.A.
THE USE OF SOCIETAL CRITERIA
IN PRIORITY SETTING FOR HEALTH
TECHNOLOGY ASSESSMENT
IN THE NETHERLANDS
initial Experiences and Future Challenges
Wija J. Oortwijn
TNO Prevention and Health
Hindrik Vondeling
Lex Bouter
Vrije Universiteit Amsterdam
Abstract
Priority setting for the evaluation of health technologies in the Netherlands is exclusively based on
the scientific merits of individual research proposals. This process has not resulted in satisfactory
allocation of resources. Therefore, societal criteria for setting priorities for health technology assess-
ment have been proposed as an adjunct to scientific criteria. These societal criteria include the burden
of disease, uncertainty about the (cost-)effectiveness of the intervention at issue, the potential benefits
of the research project, and its potential impact on health care. To realize the full potential of this
model for priority setting, a number of methodological issues need to be addressed. Joint efforts of
researchers and policy makers in this field are necessary for future progress.
Health technology assessment (HTA) in the Netherlands was introduced around
1982 when the Dutch Health Insurance Council was confronted with patients de-
manding reimbursement of the costs of heart and liver transplantations that had
been performed abroad. This debate stimulated a new policy, outlined in the paper
on limits to the expansion of the benefit package (23). The policy held stated
that, as a prerequisite for coverage in the benefit package, the efficacy and cost-
effectiveness of all major new health technologies ought to be assessed.
In 1988 the Dutch government recognized the need for a systematic approach
to HTA, which resulted in the establishment of the Investigative Medicine Pro-
gramme of the Dutch Health Insurance Council. This program, which allocates a
This article is based on an article by the same authors published in Tijdschrift voor Sociale Gezondheid-
szorg, 1996, 74, 237^4 (in Dutch).
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budget of US $21 million on an annual basis, is still the most important program
for HTA in the Netherlands. Predominantly universities and university hospitals
submit research proposals to this program. Only about 20% of research proposals
submitted to the Investigative Medicine Programme are granted as a result of
rigorous scientific assessment. The Dutch Health Insurance Council is not always
satisfied with the outcome of the selection process, as some of the selected research
proposals are not considered a high priority in Dutch health care (2;4;5;7;9;10).
Therefore, the Dutch Health Insurance Council decided to develop a model for
priority setting for HTA on the basis of societal criteria, which are to be used as
an adjunct to scientific criteria.
However, the methodology of determining the societal relevance of research
proposals is not yet established (10;28;32;43). This article reviews the initial experi-
ences with this model of priority setting and identifies some of its future challenges.
First, two procedures for submitting research proposals as part of the Investigative
Medicine Programme are described. Second, four dimensions of societal relevance
of HTA are distinguished, followed by an account of the possibilities and problems
of setting priorities under this program. To use societal criteria for priority setting
in an explicit, systematic, and transparent way, a number of methodological issues
need to be addressed.
Procedures for submitting research proposals
In the Netherlands, submission of research proposals for HTA is organized by the
Health Insurance Council in two different procedures.
The first procedure simply consists of a call for research proposals, which have
to conform to general criteria defining the borders and goal of the Investigative
Medicine Programme. In the next step the scientific quality of the submitted pro-
posals is assessed. Then, scientific criteria and, occasionally, societal criteria are
applied in a priority-setting process. This is the so-called "bottom-up" procedure
of the program. The scientific review of this procedure is very rigorous, and not
enough proposals meet scientific criteria to spend the entire annual budget. There-
fore, no priorities needed to be set beyond scientific relevance. Until 1996 about
100 research proposals have been granted within the "bottom-up" procedure, of
which 26 have been completed (19). Examples are evaluation of autologous bone
marrow transplantation for patients with malignant lymphoma and evaluation of
excimer laser coronary angioplasty (ELCA) versus percutaneous transluminal coro-
nary angioplasty (PTCA) in patients with long coronary artery stenosis.
In the second procedure, which started in 1993, selected groups of researchers
are invited to submit a full research proposal focusing on a specific subject. The
scientific merit of the research proposals is assessed. Only those proposals are
eligible for assessment that address the selected subject. This is the so-called "top-
down" approach of the program. Until mid 1996 two research proposals had been
granted: validation treatment of patients with dementia and treatment of urinary
incontinence (20;21).
As HTA consumes a fair amount of resources, it is surprising how little is
known about the effectiveness of the methods for allocation of research grants as
described above. It is unclear which method for determining societally relevant
research proposals is the best. Moreover, little is known about the efficiency of the
selection procedures.
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Societal relevance
Several attempts have been made to address the issue of determining the societal
relevance of research proposals for HTA, for example in the United States and in
the United Kingdom (12;13;27;33;34). Several criteria for setting priorities can be
found in the international literature. These criteria can be categorized in four
dimensions (7).
The first dimension is the burden of disease. Burden of disease can be described
in terms of prevalence and incidence figures, the mean burden per individual, and
the societal costs of the disease. This dimension can be characterized by a number of
indicators, of which some are available in literature, although typically information is
scarce.
The second dimension is uncertainty about the effectiveness and efficiency of
the intervention or health service at issue. This uncertainty can be inferred from
variation in use among professionals, regions and/or countries, or lack of agreement
among physicians about the indications for use. However, it is possible that existing
knowledge is available but not being consistently applied in clinical practice. More-
over, absence of clinical practice variation does not guarantee effective and efficient
care. In some cases, where multiple randomized clinical trials (RCTs) are available,
meta-analysis can be quite helpful. Information on ongoing research, which has the
potential to reduce uncertainty, is also necessary when assessing the societal rele-
vance of future research.
The third dimension is the potential benefits of the assessment. Potential bene-
fits can be an improvement in health status and/or savings in resources when, for
example, a new health technology is introduced or when an ineffective health
technology is abandoned. An estimate of the potential benefits should preferably
be based on empirical research, in which all relevant alternatives should be taken
into account.
The fourth dimension is the potential impact of the proposed research project.
This implies a necessarily subjective assessment of its potential to change clinical
practice, the organization, or the financing of care. The anticipated impact of the
assessment can be seen as a necessary criterion of societal relevance if we consider
health care research as a means to improve public health.
Setting priorities for health technology assessment
In late 1995 the Dutch Minister of Health presented a policy document about HTA
and efficiency of care to the Dutch Parliament. The policy document states that to
increase the practical application and impact of HTA research, the various activities
need to be better coordinated. Furthermore, priorities are not sufficiently well
identified (30). The Dutch Council for Health Research is charged with these tasks.
In early 1997 the Council initiated research for identifying priorities for HTA (29).
The results of the priority-setting process for HTA need to be clearly presented
before effective policy mechanisms can be implemented. In general, criteria for
setting priorities need to be derived from the goals of the funder. The level of
setting priorities also needs to be clear; priorities can be set regarding research
programs, health problems, or specific research questions or research proposals.
Setting priorities for HTA allows the resources available for research to be focused
on assessments that will contribute most to the goals of a particular program.
Although every program will have its own procedure of setting priorities, it will be
faced with several common problems.
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One problem is systematic identification of topics for priority setting. In order
to identify priorities for HTA, it is necessary to select from a pool of potential
topics. This implies the monitoring of issues that are or should be of concern to
the funders, identifying possible HTAs on these issues that could assist decision
making. Ten years ago the Steering Committee for Future Health Care Scenarios
was active in the field of monitoring health technologies. On a regular basis the
Dutch Health Council identifies relevant new health technologies for assessment.
Although this monitoring system is thought to be working quite well, more attention
should be paid to extramural technologies, nursing technologies and, new proce-
dures (30).
After identification of a potential topic, a well-defined research question needs
to be formulated. Often a research question focuses on a combination of an interven-
tion and its putative indication (9). Rapid technological developments may compli-
cate assessing new health technologies. Criteria for judging the benefit likely to
result from an assessment addressing the research question need to be well described
(32). The quality of this description depends on the availability of relevant infor-
mation.
The relative weighting of the societal criteria is also a problem in the priority-
setting process. Several methods for weighting have been proposed that are mostly
mathematically oriented (12;13;27;35). However, there is no consensus on the best
method (1;32;42). This also pertains to the way in which scientific quality is combined
with a judgment about the societal relevance of a research proposal. A solution
for this latter problem is restricting the priority-setting process to those research
proposals that are already judged to be scientifically sound.
The effort and resources needed for executing the research project at issue
also influences priority setting. A research proposal that is relatively cheap and the
societal relevance of which is judged to be modest can still be given a high priority.
Since HTA is also aimed at determining the cost-effectiveness of health care technol-
ogies, it is important to ensure that the process of assessment—including the process
of setting priorities—is cost-effective as well (42). Bonsel and Rutten (6) made a
first attempt to document this, relating the resources devoted to assessment to the
costs of health care in the case of heart and liver transplantation and in vitro
fertilization (IVF). The authors state that an assessment can be performed in a more
efficient way if researchers have experience with performing assessment studies, and
when collection of primary data is not necessary. In complementary cases, where
primary data collection is judged to be necessary, the costs of data collection should
be related to the expenditures of the technology under study (6).
These problems did not diminish the increasing attention to priority setting on
the basis of societal criteria. Examples of priority setting of general topics are
published in the report on chronic diseases by the Council for Health Research
(36) and in the Strategy Report 1996-2001 by the Board for Medical Science of
the Netherlands Organization for Scientific Research (NWO-MW) (31;41). Both
contain a description of topics based on indicators of the magnitude of the problem,
on the one hand, and available empirical evidence on the other. Experts were
consulted, but the way in which consulting was structured is not well described. In
both publications several topics are identified that should be given priority, but a
relative ranking of these topics is lacking. An attempt to rank topics was published
in a report on the cost-effectiveness analysis of existing provisions of the Dutch
Health Insurance Council (22). Two brainstorming sessions were held with medical
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advisers of insurance companies and medical insurance boards regarding the pri-
ority-setting process. The Council invited a large number of experts to judge priori-
ties for cost-effectiveness analysis of existing provisions. Experts included 11 medical
specialists, 10 general practitioners, 2 dentists, 1 nurse, and 3 hospital directors.
Finally, a list of 126 potential topics was generated, which were then ranked on the
basis of their societal relevance. The top 10 of this list include:
1. Ultrasound treatment for problems of the locomotor system;
2. Treatment and care of nonhospitalized acute psychiatric patients;
3. Specialist care for chronic patients
4. Diagnosis of suspected herniated nucleus pulposus;
5. Diagnostic arthroscopy of the knee compared to diagnostic magnetic resonance im-
aging (MRI);
6. Expanded laboratory testing by general practitioners;
7. Intensive care;
8. Palliative treatment in oncology;
9. Treatment of chronic benign pain; and
10. Electrical treatments in physiotherapy (3).
This was the first time that such a list became available in the Netherlands and the
first attempt to rationalize priority setting for HTA. This approach was debated
intensely (2;4;5;9;10;15;19;24;28;32;42;43). Although imperfect, this list was judged
to be useful for follow-up activity by both the Dutch Health Insurance Council and
the Health Council, who jointly work on the further development of the list (30).
In addition, this list is used as an input for the top-down approach of the Dutch
Health Insurance Council, which will be further described as a case study below.
The 'top-down' approach of the Dutch Fund for Investigative Medicine
The primary goal of the Dutch Fund for Investigative Medicine is to support
research that produces information on the effectiveness and efficiency of health
technology. The program also supports assessments related to the societal, ethical,
and legal aspects of the use of health technology. Both new and existing technologies
can be eligible for the program. The information should be useful for decision
making by the government and others, including providers of health care. In partic-
ular, the information should be useful to support decision making on including
programs in the social benefit package. Although, initially, a bottom-up procedure
was used to select projects, it was recognized that this approach resulted in underrep-
resentation of, among other technologies, diagnostic technologies, long-term care,
and mental health care interventions. This led the Investigative Medicine Committee
and its secretariat to consider alternative methods of selecting projects. After some
discussion, the idea of a top-down approach evolved. Based on existing priority
lists and internal discussions, three priority topics were selected: treatment of urinary
incontinence, treatment of psychogeriatric problems (especially dementia), and
assessment of diagnostic problems using MRI. Researchers could express their
interest in evaluating one of these topics by means of a short description of a
research proposal. The Committee intended to select a limited number of research
groups per topic who would receive payment for producing full-length research
proposals. This method of recruiting proposals was successful in terms of the ex-
tremely high number of descriptions of proposals that were submitted, but at the
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same time it became apparent that the research question had not been specified
sufficiently. Instead of reflecting the interests of the Investigative Medicine Com-
mittee, the priority topics had been interpreted in a way that primarily seemed to
fit the interests of the researchers. This situation complicated the selection procedure
considerably, both in the initial selection of preliminary proposals and the final
selection of full proposals. For these reasons it was decided to formulate highly
detailed research questions in preparation of the second round of the top-down
procedure. Just as the first round, the second round uses societal criteria in the
selection process. In particular, the relevance of each proposal for policy making
regarding the social benefit package should be obvious. Furthermore, the demand
for scientifically sound proposals will be fully maintained. All future proposals will
have to include a full economic evaluation: both costs and consequences of at least
two alternatives will have to be included in the study, usually organized as a RCT.
The priority-setting process should be as transparent and as explicit as possible.
In order to achieve these goals, the four dimensions of societal relevance will be
applied: burden of disease, uncertainty, the potential benefits of assessment, and
the impact of assessment. The questions related to the first three dimensions could
be answered by means of systematic literature reviews and from other sources (8).
The questions related to the fourth dimension, and to some extent with the third
dimension, may be answered primarily by systematic expert consultation. Much
attention will be paid as well to the phenomenon of unexplained clinical variation,
which pertains to clinical practice variation between physicians, regions, or countries
that cannot be attributed to differences in the prevalence of disease and/or differ-
ences in morbidity. In addition, high priority will be given to preventive health
technologies and new diagnostic technologies or therapeutic technologies that are
on the brink of rapid, uncontrolled diffusion in the health care system without
evidence of safety, effectiveness, and cost-effectiveness. Of course, this is of partic-
ular importance in the case of expensive interventions.
The starting point for this priority-setting exercise is the report on cost-effective-
ness analysis of existing provisions, the so-called "126 list" outlined above (22).
The first 50 topics of this list are selected for actual assessment. Recently the Health
Council assessed the "126 list," which resulted in a selection of 17 topics for a
synthesis of available scientific literature (18). New topics for inclusion in the
resulting "50 list" have been suggested by the Ministry of Health, university hospi-
tals, insurance companies, and medical societies. A procedure that facilitates sugges-
tions for inclusion of new topics has yet to be devised. All suggestions will be
screened using the priority-setting dimensions discussed earlier. Annually, three to
five topics will be selected for the top-down program using the "50 list" as the
source. To support the selection process, systematic literature reviews will be com-
missioned in specific cases. The proposal will be granted when it is of sufficient
methodological quality and when it demonstrates the potential to provide an ade-
quate answer to the specified research question. Of course, it is planned to periodi-
cally revise the "50 list." New topics deserving high priority will be added to the
list, while topics that have been translated into research proposals will be withdrawn
from the list. For example, in 1997 the Health Council added oral hygiene and the
treatment of dyslexia (29). Similarly, topics the priority of which is reduced due to,
for example, recent technological developments or publications of relevant studies
performed elsewhere, may be withdrawn from the list.
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DISCUSSION
Although priority setting of HTA has been tried, the methods used are typically
not very straightforward, and explicit criteria are seldom used. One reason for this
situation is that methods for setting priorities on the basis of societal criteria are
not well developed. A second reason is that crucial elements in priority setting are
still not based on sound (scientific) evidence. As a result, the priority-setting process
in the Investigative Medicine Programme faces a number of challenges. The most
important challenges include the need to balance the financing of the top-down
and the bottom-up procedure, the identification of topics for HTA, the translation
of policy-oriented questions to well-designed research questions, and the improve-
ment of the effectiveness of the priority-setting process (32).
Balance the Financing of the Top-down and the Bottom-up Procedure
The topic of balance was discussed in Parliament in May 1996, when a member of
Parliament introduced a motion urging the government to press the Health Insur-
ance Council to put more emphasis on the "126 list" by reserving less money for
the bottom-up part of the procedure. In addition, the Health Insurance Council
was asked to consider the restructuring of its Investigative Medicine Committee to
a committee devoted to reducing ineffiency in public health insurance (21). This
motion, which passed the Parliament, was fully supported by the Dutch Minister
of Health. Subsequently, the Investigative Medicine Committee decided to allocate
6 million Dutch guilders (US $3.5 million) for the top-down procedure in 1998, and
30 million Dutch guilders (US $17 million) for the bottom-up procedure. This
represents a 100% increase of the annual budget for the top-down procedure
compared to former years.
Topics for HTA
In the past, the Investigative Medicine Committee rarely accepted proposals for
the evaluation of Pharmaceuticals (20;21). This policy will become more liberal
now that the Dutch Minister of Health has allocated an additional US $11.5 million
for economic evaluation of Pharmaceuticals that are clinically significantly different
from existing pharmaceuticals, and in cases where the advent of new drugs constitute
treatment-indication combinations that did not exist before. This program will
probably be implemented in 1997.
Translation of a Policy-oriented Question to a Well-defined
Research Question
Two prerequisites can be identified for a successful "translation" of a policy-oriented
question to a well-defined research question: researchers need to be made aware
of health policy issues, and policy makers need to be made aware of assessment
procedures. This interaction could create the climate to design the assessment in
such a way that the results provide enough information for answering the policy-
oriented question. Another way to facilitate a succesful translation is to include a
section on policy-oriented issues in the application form. This has become common
practice in the Investigative Medicine Programme.
Validity of the Priority-Setting Proces
A number of national and international activities have been initiated to contribute
to improving the validity of the priority-setting process. These can be divided
according to each of the four dimensions of societal relevance.
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Regarding the first dimension, burden of disease, the report on investing in
health, by the World Bank, plays a role. This report stimulated discussion about
the concept of measuring the burden of disease, which is still controversial (40).
On the national level the National Institute for Health and Environmental Hygiene
published a major report on exploring the future of public health in 1993 (38). The
report on cost of diseases in the Netherlands by the Department of Public Health
of the Erasmus University (26) is also important in this particular context.
The activities of the Cochrane Collaboration focus on the second dimension,
aimed at the reduction of uncertainty. The Cochrane Collaboration has developed
a method for performing systematic reviews of evidence, especially evidence from
RCTs which are collected in a database (11;44). The first Cochrane Centre was set
up in the United Kingdom in 1992, and since then the Collaboration has grown
enormously. In the Netherlands a Cochrane Centre was established in 1994, funded
by the Dutch Ministry of Health (25). The Cochrane Library can be used as an
input for developing guidelines and standards for health care professionals (30).
The Collaboration is also stimulating adequate registries of ongoing research proj-
ects. This is already a tradition in social sciences but not (yet) in health sciences
and in medicine.
International activities with regard to the third dimension, the potential benefit
of the assessment, include the European projects HARMET and EUR-ASSESS.
HARMET is a project the basic aim of which is to develop consensus on the
methodology for economic evaluation of health technologies in the European
Union. Five areas were identified for operational purposes: a) definition of concepts
and terminology (e.g., health effects, benefits); b) general methodological issues
(e.g., time horizon, discount rate); c) cost measurement (e.g., consensus about
accounting rules); d) outcome measurement (e.g., consensus about health effects);
and e) presentation of results—applicability of economic analysis to decision making
(37). EUR-ASSESS is a program for communication and coordination of HTA.
Thirty-three organizations in 15 countries participated in EUR-ASSESS, divided
into four subgroups: priority setting (to improve priority setting in HTA); method-
ology (to improve methods of assessment); dissemination (to improve methods of
dissemination of HTA as well as evaluation of results); and coverage (to promote
the use of technology assessment in health insurance coverage decisions). In the
meantime a follow-up activity has been initiated, aimed at strengthening the devel-
opment of HTA in the European Community (HTA-Europe). National activities
include the Working Group Health Status Research, which was initiated in 1992
and aims at improving standards for measuring health status (14), and the report
of the Steering Committee for Future Health Care Scenarios on guidelines for cost
calculations in health services research (39).
The policy document about HTA and efficiency of care of the Dutch Ministry
of Health can be mentioned with regard to the fourth dimension, impact of assess-
ment (30). In the document much attention was given to the implementation of
assessment results. The government and several national organizations are encour-
aging professionals to implement assessment results by funding activities.
Priority setting of HTA on the basis of societal criteria creates relevant knowl-
edge for policy making. This does not necessarily imply rational policy: scientific
knowledge is just one of the many determinants of policy on the level of the
individual as well as on the societal level. However, use of societal criteria in setting
priorities of health technology assessment is necessary in making rational choices
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and improves evidence-based medicine and evidence-based health policy making
(16;17;45).
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